A Multicenter, Multi-national, Randomized, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Ciclesonide Metered-dose Inhaler (MDI) at 80 μg BID or 40 microg BID for 12 Weeks in Patients Aged 4 to less than 12 Years With Persistent Asthma.

Trial Profile

A Multicenter, Multi-national, Randomized, Double-blind, Placebo-controlled, Study to Assess the Efficacy and Safety of Ciclesonide Metered-dose Inhaler (MDI) at 80 μg BID or 40 microg BID for 12 Weeks in Patients Aged 4 to less than 12 Years With Persistent Asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Ciclesonide (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 04 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top